Plus Therapeutics presented data on ReSPECT-LM Phase 1 trial

Plus Therapeutics (PSTV) presented data updating the progress of its ReSPECT-LM Phase 1 clinical trial of Rhenium Obisbemeda in leptomeningeal disease with a specific focus on breast cancer patients. Key Highlights: Nine of 20 patients with LM primary breast cancer were treated and evaluable through five dose escalation cohorts, with the maximum tolerated dose yet to be reached. Circulating tumor cell and radiographic response data were available for 8 of the 9 breast cancer patients with LM, and clinical response data were available for 7 of the 9 patients: Best response rates were: CTC: 88%; MRI imaging 25%; Clinical 29%. Clinical benefit rates were CTC 100%; MRI imaging 75%; clinical 71%. Median overall survival for 9 breast cancer patients was 9 months, with 2 patients surviving beyond 600 days post-treatment. Next steps: Initiate ReSPECT-LM Phase 1b single-dose breast expansion cohort in Q1 2025 to further evaluate single-dose safety and efficacy of Rhenium Obisbemeda